Aktis Oncology, Inc. (AKTS) vs MannKind Corporation (MNKD)

Aktis Oncology, Inc. and MannKind Corporation are both Biotechnology companies. Aktis Oncology, Inc. and MannKind Corporation are of similar size ($1.1B and $1.1B). MannKind Corporation has the higher net margin (−11.1% vs −782.0%) and the higher return on invested capital (2.36% vs 0.00%). Across the 15 metrics below, MannKind Corporation leads on 11 and Aktis Oncology, Inc. on 4.

Valuation

Metric AKTS MNKD Biotechnology median
P/E n/m n/m 7.88
P/S 112.39 2.62 11.47
P/B 2.24 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 42.70 0.74
EV/Sales 58.83 3.41 10.73
Earnings yield (212.97%) (3.89%) (28.84%)
Free cash flow yield (12.84%) (1.76%) (23.03%)

Profitability

Metric AKTS MNKD Biotechnology median
Gross margin 100.00% 75.39% 65.16%
Operating margin (939.13%) 2.34% 0.00%
Net margin (781.95%) (11.08%) 0.00%
Free cash flow margin (1,442.91%) (4.61%) 0.00%
Return on equity (34.45%) 71.36% (57.72%)
Return on assets (27.09%) (7.62%) (49.22%)
Return on invested capital 0.00% 2.36% 0.00%

Growth

Metric AKTS MNKD Biotechnology median
Revenue growth (TTM) — 30.46% 5.64%
EPS growth (last fiscal year) (25.43%) (80.00%) —
Revenue growth, 5-year CAGR — 39.89% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS MNKD Biotechnology median
Debt to equity 0.00 (6.28) 0.00
Current ratio 16.33 1.72 4.73
Net debt to EBITDA 2.95 5.32 0.96

Dividend

Metric AKTS MNKD Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric AKTS MNKD Biotechnology median
Market cap 1.09b 1.06b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack